Thrivent Financial For Lutherans reduced its stake in Luminex Corporation (NASDAQ:LMNX) by 1.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,120 shares of the medical instruments supplier’s stock after selling 280 shares during the period. Thrivent Financial For Lutherans owned 0.05% of Luminex Corporation worth $388,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Norges Bank bought a new stake in Luminex Corporation during the fourth quarter valued at approximately $10,841,000. Elk Creek Partners LLC raised its position in shares of Luminex Corporation by 152.0% in the first quarter. Elk Creek Partners LLC now owns 698,416 shares of the medical instruments supplier’s stock valued at $12,830,000 after buying an additional 421,263 shares during the last quarter. Blair William & Co. IL acquired a new position in shares of Luminex Corporation during the first quarter valued at about $3,780,000. Dimensional Fund Advisors LP raised its position in shares of Luminex Corporation by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,685,236 shares of the medical instruments supplier’s stock valued at $34,093,000 after buying an additional 138,104 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in shares of Luminex Corporation by 13.3% in the first quarter. Neuberger Berman Group LLC now owns 968,464 shares of the medical instruments supplier’s stock valued at $17,791,000 after buying an additional 114,003 shares during the last quarter. 73.36% of the stock is owned by hedge funds and other institutional investors.

Luminex Corporation (LMNX) traded down 0.32% during mid-day trading on Friday, reaching $18.95. 138,221 shares of the company’s stock were exchanged. Luminex Corporation has a one year low of $17.64 and a one year high of $23.62. The company’s 50-day moving average is $20.30 and its 200 day moving average is $19.62. The firm has a market capitalization of $835.15 million, a P/E ratio of 58.67 and a beta of 0.29.

Luminex Corporation (NASDAQ:LMNX) last posted its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a net margin of 4.72% and a return on equity of 4.81%. The firm had revenue of $76.50 million for the quarter, compared to the consensus estimate of $75.45 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. The company’s revenue for the quarter was up 19.2% compared to the same quarter last year. Equities analysts predict that Luminex Corporation will post $0.54 earnings per share for the current fiscal year.

WARNING: “Thrivent Financial For Lutherans Lowers Stake in Luminex Corporation (LMNX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/19/thrivent-financial-for-lutherans-sells-280-shares-of-luminex-corporation-lmnx-updated-updated-updated.html.

Several brokerages recently issued reports on LMNX. BidaskClub lowered shares of Luminex Corporation from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. TheStreet lowered shares of Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. Zacks Investment Research upgraded shares of Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Monday, July 17th. ValuEngine lowered shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $21.00 price target on shares of Luminex Corporation in a research note on Friday, June 9th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $21.60.

In other news, Director G Walter Loewenbaum II sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $20.07, for a total transaction of $501,750.00. Following the transaction, the director now owns 713,896 shares in the company, valued at $14,327,892.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Stock Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related stocks with our FREE daily email newsletter.